The 180-Day Statutory Deadline and Why the Real Cycle Takes 6 to 12 Months

1. Key takeaways

The statutory review period for a CMDR is 180 days from acceptance, as set by AO No. 2018-0002. The real cycle is usually 6 to 9 months, and where a deficiency notice is issued and the response takes time it can extend to 9 to 12 months. The gap between the legal figure and the practical figure comes from two components that the statutory clock does not capture: the preparation time before submission, and the deficiency rounds after it.

• The 180 days runs from the date of acceptance, not the date the applicant sends the file, and acceptance itself is preceded by a formal completeness check and fee confirmation.
• Time spent waiting for an applicant to answer a deficiency is generally not counted inside the regulator’s review clock, which is the main reason a 180-day file can take 12 months.
• The part of the timeline that can actually be compressed is the part the applicant controls, which is the larger share of the total.
• Class A and Class B/C/D timelines differ by an order of magnitude: a CMDN runs about 1 to 3 months while a CMDR runs 6 to 12 months.
• Planning should use a range with a buffer rather than the statutory figure, and the buffer should be visible in the project plan.

2. Legal basis

The review period is set by Department of Health Administrative Order No. 2018-0002 of 26 January 2018, which requires CMDR review to be completed within 180 days of acceptance. The fast path under FC No. 2022-008 of 27 September 2022 sets a target of 30 working days where an ASEAN member state approval exists. Overall processing conduct is also governed by RA No. 11032, the Ease of Doing Business Act of 2018. For context on how the agency’s published service standards work, the FDA Citizens Charter lists 20 working days for a medical device manufacturer LTO application. The deficiency response window used in industry practice is 30 days, treated as a single opportunity.

3. Expert insights

The 180 days starts at acceptance, not at submission. The statutory clock begins when the application is accepted, and acceptance is preceded by a formal check of the documents and confirmation of the fee. Companies tend to start counting from the moment the file leaves their hands; the regulator starts counting from the moment the file is formally accepted. Between those two points sits a period that neither side counts, and it is often longer than applicants expect, particularly where the payment reference or the completeness check has to be corrected.

The deficiency period is normally outside the review clock. Once a deficiency notice is issued, the time spent waiting for the applicant to supply the missing material is generally not included in the regulator’s review time. That explains how a project described as a 180-day file ends up at 12 months. The additional time is not created by the regulator; it is created on the applicant’s side, and it is where most of the slippage in real projects accumulates.

What can genuinely be compressed is the applicant-controlled segment. Split the timeline into three parts: the applicant preparation segment covering the LTO, the dossier and the authentication; the regulatory review segment; and the deficiency interaction segment. The company can do almost nothing about the middle segment, but the preparation and deficiency segments are fully within its control. GRZAN’s experience is that a solid preparation segment, particularly LOA authentication and CSDT completeness, combined with deficiency responses completed within 5 working days, pulls the overall cycle towards the lower end of the range.

The difference between Class A and Class B/C/D is an order of magnitude, and it should drive portfolio sequencing. A CMDN takes roughly 1 to 3 months in practice, a CMDR takes 6 to 12 months. If a portfolio contains both Class A and Class B/C/D devices, they should not be expected to reach the market on the same rhythm. Treat Class A as the near-term revenue product and run the higher classes in parallel as strategic products, rather than holding the simple products back until the complex ones clear.

4. Practical recommendations

• Plan with a range plus a buffer, not with the statutory number. Estimate on 6 to 9 months and reserve a 3-month buffer inside the commercial plan so that a deficiency does not automatically move the launch date.
• Put deficiency response speed into internal KPIs. Set a target of completing and submitting the response within 5 working days of receiving the notice, measured from the day the letter arrives.
• Run the prerequisite steps in parallel. LTO processing, LOA notarisation and Apostille, and CSDT drafting should proceed simultaneously rather than in sequence, because a serial plan adds their durations together for no reason.
• Use the Abridged pathway where an ASEAN approval exists. It can shorten the review segment from 180 days to about 30 working days, which changes the whole project shape rather than just trimming it.
• Track the acceptance date as a milestone. Record the date the application is formally accepted, because that is the date every downstream commitment should be measured from.

5. Verification checklist

• □ Statutory review period confirmed as 180 days (AO No. 2018-0002).
• □ Fast path period confirmed as 30 working days where applicable (FC No. 2022-008).
• □ Start date understood as the formal acceptance date.
• □ Deficiency window of 30 days reflected in the plan as an industry figure.
• □ LTO processing of 20 working days included in the schedule (FDA Citizens Charter).
• □ Project schedule carries a buffer and is visible in the internal Gantt chart.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com